6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
and O
Behaviors O
in O
Children O
, O
Adolescents O
, O
and O
Young O
Adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Increased O
Risk O
of O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Activation O
of O
Mania B-OSE_Labeled_AE
or O
Hypomania B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Seizures B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Closure I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
: O
diarrhea O
, O
nausea O
, O
vomiting O
, O
and O
insomnia O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Forest O
Laboratories O
, O
LLC O
. O

at O
1-800-678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
and O
varying O
lengths O
of O
time O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
rates O
observed O
in O
practice O
. O

The O
most O
commonly O
observed O
adverse O
reactions O
in O
VIIBRYD-treated O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
MDD O
) O
in O
placebo-controlled O
studies O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
were O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Patient O
Exposure O
The O
safety O
of O
VIIBRYD O
was O
evaluated O
in O
3,007 O
patients O
( O
18-70 O
years O
of O
age O
) O
diagnosed O
with O
MDD B-Not_AE_Candidate
who O
participated O
in O
clinical O
studies O
, O
representing O
676 O
patient-years O
of O
exposure O
. O

In O
an O
open-label O
52 O
week O
study O
at O
40 O
mg O
daily O
, O
599 O
patients O
were O
exposed O
to O
VIIBRYD O
for O
a O
total O
of O
348 O
patient-years O
. O

The O
adverse O
reaction O
information O
presented O
below O
was O
derived O
from O
studies O
of O
VIIBRYD O
20 O
mg O
and O
40 O
mg O
daily O
in O
patients O
with O
MDD O
including O
: O
* O
Four O
placebo-controlled O
8 O
to O
10-week O
studies O
in O
2,233 O
patients O
, O
including O
1,266 O
VIIBRYD-treated O
patients O
; O
and O
* O
An O
open-label O
52-week O
study O
of O
599 O
VIIBRYD-treated O
patients O
. O

These O
studies O
included O
a O
titration O
period O
of O
10 O
mg O
daily O
for O
7 O
days O
, O
followed O
by O
20 O
mg O
daily O
for O
7 O
days O
or O
to O
40 O
mg O
daily O
over O
2 O
weeks O
. O

In O
these O
clinical O
trials O
, O
VIIBRYD O
was O
administered O
with O
food O
. O

Adverse O
reactions O
reported O
as O
reasons O
for O
discontinuation O
of O
treatment O
In O
these O
studies O
, O
7.3 O
% O
of O
the O
VIIBRYD-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
3.5 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
discontinuation O
in O
at O
least O
1 O
% O
of O
the O
VIIBRYD-treated O
patients O
in O
the O
placebo-controlled O
studies O
was O
nausea B-OSE_Labeled_AE
( O
1.4 O
% O
) O
. O

Common O
adverse O
reactions O
in O
placebo-controlled O
MDD O
studies O
Table O
2 O
shows O
the O
incidence O
of O
common O
adverse O
reactions O
occuring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
patients O
and O
greater O
than O
the O
rate O
of O
placebo-treated O
patients O
in O
MDD O
Studies O
. O

There O
were O
no O
dose-related O
adverse O
reactions O
between O
20 O
mg O
and O
40 O
mg O
reported O
. O

Table O
2 O
: O
Common O
Adverse O
Reactions O
Occurring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
Patients O
and O
Greater O
than O
the O
Rate O
of O
Placebo-Treated O
Patients O
System O
Organ O
Class O
Preferred O
Term O
Placebo O
N=967 O
VIIBRYD O
20 O
mg/day O
N=288 O
VIIBRYD O
40 O
mg/day O
N=978 O
1 O
Includes O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

2 O
Includes O
headache B-OSE_Labeled_AE
and O
tension B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
3 O
Includes O
restlessness B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
and O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Sexual O
adverse O
reactions O
are O
presented O
in O
Table O
3 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
10 O
% O
26 O
% O
29 O
% O
Nausea B-OSE_Labeled_AE
7 O
% O
22 O
% O
24 O
% O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
5 O
% O
8 O
% O
7 O
% O
Vomiting B-OSE_Labeled_AE
2 O
% O
4 O
% O
5 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
3 O
% O
7 O
% O
4 O
% O
Dyspepsia B-OSE_Labeled_AE
2 O
% O
2 O
% O
3 O
% O
Flatulence B-OSE_Labeled_AE
1 O
% O
3 O
% O
3 O
% O
Gastroenteritis B-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
1 O
% O
2 O
% O
1 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
2 O
14 O
% O
15 O
% O
14 O
% O
Dizziness B-OSE_Labeled_AE
5 O
% O
6 O
% O
8 O
% O
Somnolence B-OSE_Labeled_AE
2 O
% O
4 O
% O
5 O
% O
Paresthesia B-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
2 O
% O
7 O
% O
6 O
% O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
2 O
% O
2 O
% O
3 O
% O
Restlessness B-OSE_Labeled_AE
3 O
1 O
% O
2 O
% O
3 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
3 O
% O
4 O
% O
3 O
% O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
< O
1 O
% O
1 O
% O
2 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
% O
1 O
% O
3 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
1 O
% O
2 O
% O
1 O
% O
Investigations B-NonOSE_AE
Increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Sexual O
adverse O
reactions O
Table O
3 O
displays O
the O
most O
common O
sexual O
adverse O
reactions O
in O
the O
placebo-controlled O
MDD O
studies O
. O

Table O
3 O
: O
Common O
Sexual O
Adverse O
Reactions O
Occurring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
Patients O
and O
Greater O
than O
the O
Rate O
of O
Placebo-Treated O
Patients O
- O
Not O
applicable*Includes O
abnormal B-OSE_Labeled_AE
orgasm I-OSE_Labeled_AE
and O
anorgasmia B-OSE_Labeled_AE
Preferred O
Term O
Males O
Females O
Placebo O
N=416 O
VIIBRYD O
20 O
mg/day O
N=122 O
VIIBRYD O
40 O
mg/day O
N=417 O
Placebo O
N=551 O
VIIBRYD O
20 O
mg/day O
N=166 O
VIIBRYD O
40 O
mg/day O
N=561 O
Abnormal B-OSE_Labeled_AE
Orgasm I-OSE_Labeled_AE
* I-OSE_Labeled_AE
< O
1 O
% O
2 O
% O
2 O
% O
0 O
% O
1 O
% O
1 O
% O
Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
1 O
% O
0 O
% O
3 O
% O
- O
- O
- O
Libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
< O
1 O
% O
3 O
% O
4 O
% O
< O
1 O
% O
2 O
% O
2 O
% O
Ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
0 O
% O
1 O
% O
2 O
% O
- O
- O
- O
Other O
adverse O
reactions O
observed O
in O
clinical O
studies O
The O
following O
list O
does O
not O
include O
reactions O
: O
1 O
) O
already O
listed O
in O
previous O
tables O
or O
elsewhere O
in O
labeling O
, O
2 O
) O
for O
which O
a O
drug O
cause O
was O
remote O
, O
3 O
) O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
4 O
) O
which O
were O
not O
considered O
to O
have O
significant O
clinical O
implications O
, O
or O
5 O
) O
which O
occurred O
at O
a O
rate O
equal O
to O
or O
less O
than O
placebo O
. O

Reactions O
are O
categorized O
by O
body O
system O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
reactions O
are O
those O
occurring O
in O
at O
least O
1/100 O
patients O
; O
infrequent O
adverse O
reactions O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
reactions O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
: O
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
rare O
: O
cataracts B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
sedation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
; O
infrequent O
: O
migraine B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
hyperhidrosis B-OSE_Labeled_AE
, O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
6.2 O
Post-marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VIIBRYD O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Reports O
of O
adverse O
reactions O
temporally O
associated O
with O
VIIBRYD O
that O
have O
been O
received O
since O
market O
introduction O
and O
that O
are O
not O
listed O
above O
include O
the O
following O
: O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
irritability B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hallucinations B-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
rash B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
eruption I-OSE_Labeled_AE

